These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19333002)

  • 1. A comparison of immunogenicity and safety of indigenously developed liquid (DTwPHB-Hib) pentavalent combination vaccine (Shan 5) with Easyfive (liq) and TritanrixHB + Hiberix (lyo) in Indian infants administered according to the EPI schedule.
    Rao R; Dhingra MS; Bavdekar S; Behera N; Daga SR; Dutta AK; Kundu R; Maiya P; Mishra P; Shah R; Shuba S; Tibrewala V; Pandhi S; Rajamani AM
    Hum Vaccin; 2009 Jun; 5(6):425-9. PubMed ID: 19333002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Shan 4) with EasyFourTM in Indian infants administered per EPI schedule: a phase III trial.
    Dhingra MS; Rao R; Bhat S; Joshi R; Kalra V; Parikh HR; Rao SN; Sethi GR; Shah N; Muzaffaruddin M
    Hum Vaccin; 2010 Jul; 6(7):572-7. PubMed ID: 20421723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.
    Chatterjee S; Rego SJ; D'Souza F; Bhatia BD; Collard A; Datta SK; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():298. PubMed ID: 20950457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.
    Sharma HJ; Yadav S; Lalwani SK; Kapre SV; Jadhav SS; Chakravarty A; Parekh SS; Palkar S; Bhardwaj SH; Namjoshi GS; Verma V
    Hum Vaccin; 2011 Apr; 7(4):451-7. PubMed ID: 21403463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.
    Eregowda A; Lalwani S; Chatterjee S; Vakil H; Ahmed K; Costantini M; Lattanzi M
    Hum Vaccin Immunother; 2013 Sep; 9(9):1903-9. PubMed ID: 23783081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
    Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L
    Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw-HBV-Hib, a liquid pentavalent vaccine in Indian infants.
    Sharma H; Yadav S; Lalwani S; Gupta V; Kapre S; Jadhav S; Chakravarty A; Parekh S; Palkar S
    Vaccine; 2011 Mar; 29(13):2359-64. PubMed ID: 21288803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S; Reyes M; Bermal N; Chandrasekaran V; Han HH; Bock HL; Lefevre I
    Hum Vaccin; 2008; 4(1):60-6. PubMed ID: 18376148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization.
    Li G; Zhang H; Zhou W; Ye Q; Li F; Wang H; Hou Q; Xu Y; Ma X; Tan Y; Wang L; Li Y; Li H; Meng F; Liang Q; Liu A; Qin C; Wei W; Liu J; Ruan C; Tao W; Zhang S; Zheng H; Zhu F
    Vaccine; 2010 Jun; 28(25):4215-23. PubMed ID: 20399240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants.
    Bavdekar SB; Maiya PP; Subba Rao SD; Datta SK; Bock HL
    Indian Pediatr; 2007 Jul; 44(7):505-10. PubMed ID: 17684303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants.
    Gandhi DJ; Dhaded SM; Ravi MD; Dubey AP; Kundu R; Lalwani SK; Chhatwal J; Mathew LG; Gupta M; Sharma SD; Bavdekar SB; Jayanth MV; Ravinuthala S; Sil A; Dhingra MS
    Hum Vaccin Immunother; 2016 Apr; 12(4):946-54. PubMed ID: 26580093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
    Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine).
    Ali SS; Chandrashekar SR; Singh M; Bansal RK; Sharma DR; Arora D
    Hum Vaccin; 2007; 3(4):116-20. PubMed ID: 17617743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine.
    Sharma H; Yadav S; Lalwani S; Kapre S; Jadhav S; Parekh S; Palkar S; Ravetkar S; Bahl S; Kumar R; Shewale S
    Vaccine; 2013 Jan; 31(3):444-7. PubMed ID: 23196204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A
    Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.